Matsumoto Ken'ichiro, Aoki Emi, Takase Kazuma, Doi Yoshiharu, Taguchi Seiichi
Department of Biological Science and Technology, Tokyo University of Science, Yamazaki 2641, Noda, Chiba 278-8510, Japan.
Biomacromolecules. 2006 Aug;7(8):2436-42. doi: 10.1021/bm0602029.
Evolutionary engineered polyhydroxyalkanoate (PHA) synthases from Pseudomonas sp. 61-3 enhance PHA accumulation and enable the monomer composition of PHAs to be regulated. We characterized a newly screened Ser477Arg (S477R) mutant of PHA synthase by in vivo analyses of P(3-hydroxybutyrate) [P(3HB)] homopolymer and P(3HB-co-3-hydroxyalkanoate) [P(3HB-co-3HA)] copolymer productions in the recombinants of Escherichia coli. The results indicated that the S477R mutation contributed to a shift in substrate specificity to smaller monomers containing a 3HB unit rather than to an enhancement in catalytic activity. Multiple mutations of S477R with other beneficial mutations, for example, Ser325Cys, exhibited synergistic effects on both an increase in PHA production (from 9 wt % to 21 wt %) and an alteration of substrate specificity. Furthermore, the effects of complete amino acid substitutions at position 477 were characterized in terms of in vivo PHA production and in vitro enzymatic activity. The five mutations, S477Ala(A)/Phe(F)/His(H)/Arg(R)/Tyr(Y), resulted in a shift in substrate specificity to smaller monomer units. The S477Gly(G) mutant greatly enhanced activity toward all different sizes of substrates with carbon numbers ranging from 4 to 12. These results indicated that the residue 477 contributes to both the catalytic activity and substrate specificity of PHA synthase. In recombinant E. coli, the S477A/F/G/H/R/Y mutations consistently led to increases (up to 6 times that of wild-type enzyme) in weight average molecular weights of P(3HB) homopolymers. On the basis of our studies, we created a structural feasibility accounting for the mutational effects on enzymatic activity and substrate specificity of PHA synthase.
来自假单胞菌属61-3的进化工程聚羟基脂肪酸酯(PHA)合酶可增强PHA积累,并使PHA的单体组成得以调控。我们通过对大肠杆菌重组体中聚(3-羟基丁酸酯)[P(3HB)]均聚物和聚(3-羟基丁酸酯-co-3-羟基链烷酸酯)[P(3HB-co-3HA)]共聚物生产进行体内分析,对新筛选出的PHA合酶Ser477Arg(S477R)突变体进行了表征。结果表明,S477R突变导致底物特异性向含3HB单元的较小单体转变,而非催化活性增强。S477R与其他有益突变(如Ser325Cys)的多重突变对PHA产量增加(从9 wt%增至21 wt%)和底物特异性改变均表现出协同效应。此外,还根据体内PHA产量和体外酶活性对477位完全氨基酸取代的影响进行了表征。这五个突变,即S477Ala(A)/Phe(F)/His(H)/Arg(R)/Tyr(Y),导致底物特异性向较小单体单元转变。S477Gly(G)突变体对碳数范围为4至12的所有不同大小底物的活性均有极大增强。这些结果表明,477位残基对PHA合酶的催化活性和底物特异性均有贡献。在重组大肠杆菌中,S477A/F/G/H/R/Y突变始终导致P(3HB)均聚物的重均分子量增加(最高可达野生型酶的6倍)。基于我们的研究,我们创建了一个结构可行性模型,以解释对PHA合酶酶活性和底物特异性的突变效应。